Literature DB >> 4080986

Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB).

C M Arundel, A S Glicksman, J T Leith.   

Abstract

Two subpopulations of human colon tumor cells (clones A and D) which differ in their intrinsic sensitivity to X irradiation were grown for several passages in tissue culture medium containing the differentiation-inducing agent sodium butyrate (NaB, 2 mM). Values of the single-hit, multitarget survival curve parameters for non-NaB-treated clone A cells were n = 17.1, D0(Gy) = 0.81, and DQ(Gy) = 2.31; corresponding parameters for NaB-treated cells were 1.04, 1.16, and 0.05. For non-NaB-treated clone D cells, the survival parameters were n = 4.27, D0 = 1.05, and DQ = 1.52; corresponding parameters for NaB-treated cells were 1.19, 1.15, and 0.20. The large reduction in the DQ parameters of both clone A and D cells after NaB treatment indicates that sodium butyrate-induced cell maturation is accompanied by increase in radiation cell kill, particularly in the low-dose region of the survival curve.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4080986

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  14 in total

1.  Contribution of decreased expression of Ku70 to enhanced radiosensitivity by sodium butyrate in glioblastoma cell line (U251).

Authors:  Yuhui Li; Hongxia Zhou; Enming Xing; Meera Dassarath; Jinghua Ren; Xiaorong Dong; Hongli Liu; Kunyu Yang; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

Review 2.  Histone deacetylase inhibitor: antineoplastic agent and radiation modulator.

Authors:  Zacharoula Konsoula; Alfredo Velena; Rachel Lee; Anatoly Dritschilo; Mira Jung
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

3.  A histone deacetylase inhibitor, trichostatin A, enhances radiosensitivity by abrogating G2/M arrest in human carcinoma cells.

Authors:  In Ah Kim; Jin Ho Kim; Jin Hee Shin; Il Han Kim; Jae Sung Kim; Hong-Gyun Wu; Eui Kyu Chie; Yong Ho Kim; Bo-Kyung Kim; Semie Hong; Seok Won Park; Sung Whan Ha; Charn Il Park
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

4.  The intervention of valproic acid on the tumorigenesis induced by an environmental carcinogen of PAHs.

Authors:  Junxuan Peng; Zuchao Cai; Ruixue Zhao; Jiahao Chen; Guochao Liu; Chao Dong; David Lim; Zhihui Feng
Journal:  Toxicol Res (Camb)       Date:  2020-08-31       Impact factor: 3.524

5.  Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma.

Authors:  M Perona; C Rodríguez; M Carpano; L Thomasz; S Nievas; M Olivera; S Thorp; P Curotto; E Pozzi; S Kahl; M Pisarev; G Juvenal; A Dagrosa
Journal:  Radiat Environ Biophys       Date:  2013-05-01       Impact factor: 1.925

6.  Effects of differentiation-inducing agents on purine nucleotide metabolism in an ovarian cancer cell line.

Authors:  E Zoref-Shani; R Lavie; Y Bromberg; E Beery; Y Sidi; O Sperling; J Nordenberg
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Molecular targets for tumor radiosensitization.

Authors:  Philip J Tofilon; Kevin Camphausen
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 8.  Epigenetic Deregulation of Apoptosis in Cancers.

Authors:  Ezgi Ozyerli-Goknar; Tugba Bagci-Onder
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

9.  The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines.

Authors:  Hang Joo Cho; Sin Young Kim; Kee Hwan Kim; Won Kyung Kang; Ji Il Kim; Seong Tack Oh; Jeong Soo Kim; Chang Hyeok An
Journal:  World J Surg Oncol       Date:  2009-05-21       Impact factor: 2.754

10.  Histone deacetylase inhibition and dietary short-chain Fatty acids.

Authors:  Paul V Licciardi; Katherine Ververis; Tom C Karagiannis
Journal:  ISRN Allergy       Date:  2011-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.